Skip to main content
Back
Watch Compare

Silence Therapeutics plc

Data quality: 100%
Also listed as SLNCF Nasdaq
SLN
Nasdaq Manufacturing Chemicals
$5.66
▼ $0.19 (-3.25%)
Mkt Cap: 267.34 M
Price
$5.66
Mkt Cap
267.34 M
Day Range
$5.57 — $5.77
52-Week Range
$1.97 — $7.91
Volume
149,614
Open $5.76
50D / 200D Avg
$5.46
3.62% above
50D / 200D Avg
$5.82
2.80% below

Quick Summary

Key Takeaways

Negative free cash flow of -62.33 M
Capital efficient — spends only 9.84% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-98.71%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-105.35%
Below sector avg (-53.41%)
ROIC-51.42%
Net Margin-15851.88%
Op. Margin-16292.84%

Safety

Debt / Equity
N/A
Current Ratio7.69
Interest CoverageN/A

Valuation

PE (TTM)
-3.02
Below sector avg (-1.48)
P/B Ratio3.61
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -3.0 -1.5
P/B 3.6 1.6
ROE % -105.4 -53.4
Net Margin % -15851.9 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0.89% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -98.71% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 559,000.0 Net Income (TTM) -88.61 M
ROE -105.35% ROA -56.80%
Gross Margin 61.54% Operating Margin -16292.84%
Net Margin -15851.88% Free Cash Flow (TTM) -62.33 M
ROIC -51.42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.69
Interest Coverage N/A Asset Turnover 0.00
Working Capital 116.25 M Tangible Book Value 63.45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.02 Forward P/E N/A
P/B Ratio 3.61 P/S Ratio 478.25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -23.31%
Market Cap 267.34 M Enterprise Value 185.31 M
Per Share
EPS (Diluted TTM) -0.63 Revenue / Share 0.01
FCF / Share -1.32 OCF / Share -1.32
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 9.84% FCF Conversion 70.34%
SBC-Adj. FCF -70.40 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 559,000.0 43.26 M
Net Income -88.61 M -45.31 M
EPS (Diluted) -0.63 -0.33
Gross Profit 344,000.0 31.45 M
Operating Income -91.08 M -63.32 M
EBITDA — —
R&D Expenses 67.75 M 67.88 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax 11,000.0 845,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 131.44 M 202.64 M
Total Liabilities 69.14 M 68.61 M
Shareholders' Equity 62.30 M 134.02 M
Total Debt — —
Cash & Equivalents 11.28 M 121.33 M
Current Assets 118.66 M 187.37 M
Current Liabilities 13.61 M 16.82 M